ライフサイエンスコーパス: metastases

1 eg, alpha = .08 for intraparenchymal splenic metastases).

2 umour, metastatic tumour size, and number of metastases.

3 4 to 6 months is reasonable for men without metastases.

4 ne still corresponded with a lack of distant metastases.

5 mediastinal lymphadenopathy without distant metastases.

6 % of patients with cancer will develop brain metastases.

7 ision, whole-organ resection, and peritoneal metastases.

8 , and 1 or 2 sentinel lymph nodes containing metastases.

9 ts with ipsilateral axillary lymph node (LN) metastases.

10 rogression and a higher number of lymph node metastases.

11 uction algorithms for the detection of liver metastases.

12 d-type-like properties in prevention of lung metastases.

13 lular carcinomas, were also mutated in liver metastases.

14 tures unique to fibrosis, primary tumors, or metastases.

15 stage breast cancer without overt lymph node metastases.

16 genetic material from the primary tumor and metastases.

17 sions in primary tumors and colorectal liver metastases.

18 elated events and pain in patients with bone metastases.

19 ective against distant solid tumors and lung metastases.

20 the low prevalence of patients with osseous metastases.

21 ty between primary tumours and their distant metastases.

22 R-mutant NSCLC with brain and leptomeningeal metastases.

23 ow from colorectal cancer patients with bone metastases.

24 ty was observed within the group of melanoma metastases.

25 as not been studied in active melanoma brain metastases.

26 , tumor invasion, and development of distant metastases.

27 d the cause of most deaths is leptomeningeal metastases.

28 d for the ability to visualize HER2-positive metastases.

29 as performed for resection of bilateral lung metastases.

30 nts with EGFR-mutant NSCLC who develop brain metastases.

31 ous metastasis yet decreases ccRCC lymphatic metastases.

32 ove outcomes in patients with melanoma brain metastases.

33 prior systemic therapy and presence of liver metastases.

34 ked inhibition of both tumor growth and lung metastases.

35 the limited number of patients and available metastases.

36 eages of two CRC patients with matched liver metastases.

37 s associated with formation of prostate bone metastases.

38 tions in pancreatic primary tumors and liver metastases.

39 s met Z0011 eligibility criteria and had SLN metastases.

40 e, and dramatically reduces CTC-derived lung metastases.

41 ivary gland cancers with a high incidence of metastases.

42 senting with neuroendocrine tumor (NET) with metastases.

43 local tumor, lymph node metastases, and bone metastases.

44 lates tumor progression from adenoma through metastases.

45 nto tumors and thereby tumor progression and metastases.

46 nous hyperinsulinemia promotes mammary tumor metastases.

47 n metastatic prostate cancer, including bone metastases.

48 normal lung, fibrotic lung, lung tumors, and metastases.

49 form a premetastatic niche to promote liver metastases.

50 = 3 v > 3 months) and nodal versus non-nodal metastases.

51 225) Ac TAT for the treatment of soft-tissue metastases.

52 ons of radioembolization of colorectal liver metastases.

53 or triple-negative subtypes and extracranial metastases.

54 extracranial metastases, and number of brain metastases.

55 so underwent SRS for additional intracranial metastases.

56 miting NK cell-mediated control of pulmonary metastases.

57 iagnosis and optimal treatment of intestinal metastases.

58 models reduced the number of mice with organ metastases.

59 opy should be correlated between synchronous metastases.

60 of BMAs in control of pain secondary to bone metastases.

61 geneous receptor expression in breast cancer metastases.

62 g treatment response in prostate cancer bone metastases.

63 seen in primary tumor lesions as well as in metastases.

64 radiotherapy was encouraged for men without metastases.

65 ger and thus are at increased risk for brain metastases.

66 n-resistant prostate cancer without visceral metastases.

67 icity profile in salvage patients with liver metastases.

68 ypical lesions were more commonly unusual PC metastases (1.0%) or benign (3.1%).

69 . 7 vs. 15), and differences in size of lung metastases (1.2 vs. 1.4 vs. 1.0 mm diameter) compared wi

70 , and 1 or 2 sentinel lymph nodes containing metastases, 10-year overall survival for patients treate

71 (262 vs. 293 vs. 225 days), fewer pulmonary metastases (5 vs. 7 vs. 15), and differences in size of

72 rogenous in primary tumors yet homogenous in metastases, a pattern consistent with activated Kras(mut

73 In those patients identified as having bone metastases according to the reference standard, SPECT/CT

74 Metastases account for the great majority of cancer-asso

75 data of 12 treatment-naive patients with 34 metastases acquired before and at one, two, and three mo

76 important mediator of PCa bone and visceral metastases, activating paracrine Shh signaling in tumor-

77 atients with colorectal cancer develop liver metastases after resection of the primary tumor, and sur

78 ified as an important risk stratifier for LN metastases, after mitoses and thickness.

79 t (PDX) models from patient-derived HTR bone metastases and analyzed tumor cells, stroma, and microve

80 f KLF10 in PDAC is shown to increase distant metastases and cancer stemness through activation of SDF

81 otein 78 (GRP78) are highly expressed in PCa metastases and display higher levels in the metastatic A

82 or ROS1-positive NSCLC, most of whom had CNS metastases and had previously had two or more TKI treatm

83 nts with EGFR-mutant NSCLC who develop brain metastases and have not received EGFR-TKI.

84 increase PSMA expression in prostate cancer metastases and increase the number of lesions visualized

85 y associated with the presence of lymph node metastases and invasive tumor stages.

86 In patients with radiographic evidence of metastases and minimal symptoms, enzalutamide or abirate

87 We found that human colorectal cancer liver metastases and murine gastrointestinal experimental live

88 n and median survival of patients with brain metastases and newly diagnosed breast cancer.

89 40 hormone-refractory patients with distant metastases and progressive disease (mean age, 71.4 y).

90 diverse presentation of intestinal melanoma metastases and the diagnostic and therapeutic dilemmas i

91 n assessment of associations between distant metastases and tumor characteristics was a second object

92 hylation was observed in cells isolated from metastases and was associated with poor survival of colo

93 oup) were ineligible because of pre-existing metastases and were therefore excluded from the analysis

94 have received prior therapy for their brain metastases and whose CNS disease is radiographically sta

95 ovarian carcinoma tumors, secondary omental metastases, and ascites cells isolated from serous ovari

96 e in the primary tumor, soft tissue and bone metastases, and bone marrow.

97 (18)F-PSMA-1007 for local tumor, lymph node metastases, and bone metastases.

98 use, prior taxane use, presence of visceral metastases, and Eastern Cooperative Oncology Group score

99 32 patients with matched primary tumors and metastases, and found a high level of concordance (85.7%

100 els were built for overall survival, distant metastases, and local recurrence using only clinical fac

101 , Karnofsky Performance Status, extracranial metastases, and number of brain metastases.

102 ent tumor cell killing in primary tumors and metastases, and that these effects can be amplified by c

103 e treatment or prophylaxis of leptomeningeal metastases, and the cause of most deaths is leptomeninge

104 urine metabolism, were detected in 4/5 liver metastases, and the same four liver metastases shared mu

105 Hepatic metastases are amenable to ablation; however, many patie

106 uncommon site for neoplastic involvement and metastases are far commoner than primary neoplasms.

107 d murine gastrointestinal experimental liver metastases are infiltrated by neutrophils.

108 Uveal metastases are ophthalmologic tumors that have historica

109 that in 65% of cases, lymphatic and distant metastases arose from independent subclones in the prima

110 adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at screening

111 latency and reduced growth, with fewer lung metastases, as compared with Hic-5(+/-);PyMT mice.

112 identify predictors of the presence of brain metastases at diagnosis and factors associated with all-

113 13 for whom the presence or absence of brain metastases at diagnosis was known.

114 se of widespread dissemination of peritoneal metastases at diagnosis.

115 n were associated with lower risk of distant metastases at follow-up in univariate analysis (Log-rank

116 als of patients with breast cancer and brain metastases at the time of cancer diagnosis.

117 A higher rate of undetected metastases at the time of diagnosis in younger women has

118 We identified 968 patients with brain metastases at the time of diagnosis of breast cancer, re

119 Patients with breast cancer and brain metastases at the time of diagnosis were identified usin

120 ion-to-treat population (3 had overt distant metastases at the time of randomization; 2 withdrew cons

121 ses, defined as new and/or progressive brain metastases at the time of study entry; and those with le

122 idence and prognosis for patients with brain metastases at time of diagnosis of breast cancer.

123 f arm lymphatics, crossover rates, blue node metastases, axillary recurrence, and lymphedema as measu

124 d as having potentially resectable abdominal metastases before (1969-2003) and after (2004-2014) adva

125 Patients with breast cancer (BrCa) brain metastases (BrM) have limited therapeutic options.

126 not only in a higher detection rate of liver metastases but also in a significantly higher lesion-bas

127 reatment-refractory breast cancer chest wall metastases but responses are short-lived.

128 or photothermal ablation of colorectal liver metastases by increasing ablation zones.

129 ment and reduces tumour burden and pulmonary metastases by modulating macrophage phenotypes.

130 d chemotherapy, and it eliminated lymph node metastases by targeting CSCs and the tumor bulk, suggest

131 operative complications for colorectal liver metastases (CLM) in the era of RAS mutation analysis.

132 had a complete resection of colorectal liver metastases (CLM).

133 motherapy and resection for colorectal liver metastases (CLM).

134 ia (RLI) after resection of colorectal liver metastases (CLMs) is unknown to date.

135 Remarkably, distant metastases co-evolved a dependence on the oxidative bran

136 PIK3CA mRNA levels were increased in metastases compared to the primary tumors (p = 0.031), i

137 imary tumors and greater number of pulmonary metastases compared with wild-type (WT) mice after injec

138 ate tumors and are further enriched in human metastases, correlating with survival.

139 ver malignancies, including colorectal liver metastases (CRLM) ( 1 ).

140 outcomes after resection of colorectal liver metastases (CRLM) and concurrent extrahepatic disease (E

141 KRAS-mutated colorectal liver metastases (CRLM) are known to be more aggressive than K

142 able at study entry; those with active brain metastases, defined as new and/or progressive brain meta

143 populations: those with treated/stable brain metastases, defined as patients who have received prior

144 d Prevotella species-is maintained in distal metastases, demonstrating microbiome stability between p

145 andomly assigned patients with sentinel-node metastases detected by means of standard pathological as

146 e tumour with no established treatments once metastases develop.

147 found in 1833 patients with NSCLC and brain metastases diagnosed between 1985 and 2005: patient age,

148 of locoregional recurrences (LR) and distant metastases (DM) in head-and-neck cancer.

149 Tumors occur throughout the stomach, with metastases documented in lymph nodes, lung, and liver.

150 s, mice lacking PITPalpha develop fewer lung metastases due to a reduction of fibrin formation surrou

151 Among patients with bone metastases due to breast cancer, prostate cancer, or mul

152 diagnosed the lesions as disseminated brain metastases due to lung cancer.

153 wever, they can also be due to hypercellular metastases, even if no contrast enhancement is observed.

154 Brain metastases expression changes in 127 genes within BrCa s

155 y prove useful in targeting cancer cells and metastases for tumor diagnosis, imaging, and therapy.

156 into body fluids might be closely related to metastases formation.

157 bryonal cancer of neural crest origin, shows metastases frequently at diagnosis.

158 shift in indications toward colorectal liver metastases from 53% to 77% and a reverse trend in biliar

159 arried out 60x whole-genome sequencing of 26 metastases from four patients with pancreatic cancer.

160 adiotherapy required to treat multiple brain metastases from non-small-cell lung cancer when highly a

161 s (1.0%), lesions were proven to be atypical metastases from PC.

162 for outcome prediction in patients with bone metastases from PC.

163 rthle cell, 2 medullary, 1 follicular, and 4 metastases from underlying malignancy).

164 etastases-including brain and leptomeningeal metastases-from epidermal growth factor receptor (EGFR)-

165 In vivo tumor control of B16F10 lung metastases further confirmed the variant DTT-IYG to be t

166 ma associated with the rare and much smaller metastases generated by the same cells in IL-1R knockout

167 Analogously, the stroma adjacent to skeletal metastases generated in mice by IL-1beta-expressing canc

168 All (18)F-FET-negative metastases had a diameter of </= 1.0 cm, whereas metasta

169 ons in the liver and lungs whereas the brain metastases had nearly resolved.

170 ptomatic or untreated central nervous system metastases, had received anticancer therapy 14 days or f

171 The treatment of intestinal melanoma metastases has changed due to the introduction of novel

172 analyses of somatic mutations show that the metastases have a monoclonal origin and descend from a c

173 Historically, patients with brain metastases have been understudied, because of restrictiv

174 ymphocytes in primary colon tumors and liver metastases have improved outcomes.

175 Finally, TNBC lung metastases have lower LD abundance than their correspond

176 me chemotherapeutic resistance and eliminate metastases have not yet been identified.

177 00)-mutant metastatic melanoma without brain metastases; however, the activity of dabrafenib plus tra

178 ents, there was concordance in the number of metastases identified with (68)Ga-HBED-PSMA-11 and (68)G

179 Nonsentinel-node metastases, identified in 11.5% of the patients in the d

180 Forty-five brain metastases in 30 patients were included.

181 complete regression of pre-existing distant metastases in 65% of the animals and a significant reduc

182 ography revealed partial response of hepatic metastases in 7 patients (25%) by one observer and in 10

183 d vascularization of primary tumors and lung metastases in a breast cancer xenograft model as well as

184 viability - leads to elimination of distant metastases in a mouse model of metastatic breast cancer.

185 y reduced whole body, lung, kidney and liver metastases in an experimental metastases mouse model.

186 garding the inclusion of patients with brain metastases in clinical trials, as part of a broader effo

187 of the interstitial space were observed for metastases in comparison to HCCs (P < 0.05).

188 hosphonates can reduce the incidence of bone metastases in early breast cancer.

189 Notably, mice with metastases in fatty versus lean livers were associated w

190 n of GM-CSF positively correlates with local metastases in lymph nodes.

191 ing kinase (ULK1) mutant K46N increased lung metastases in MDA-MB-231 xenograft mouse models.

192 The intestine is a frequent site of metastases in melanoma patients.

193 specific localization to breast cancer bone metastases in mice.

194 spite the fairly rare prevalence of cerebral metastases in NENs, a neurological work-up should be per

195 Rates of metastases in noncrossover nodes and axillary recurrence

196 93.2%) had lymph nodes harvested, with nodal metastases in only 14 (34.1%).

197 PET/CT is a new method to detect early nodal metastases in patients with biochemical relapse of prost

198 itors (TKIs) are treatment options for brain metastases in patients with EGFR-mutant non-small-cell l

199 an important therapeutic strategy to reduce metastases in patients with obesity, pre-diabetes or T2D

200 n many solid tumors and impacts survival and metastases in patients.

201 Whether ITPP protects from distant metastases in primary colon cancer is unknown.

202 Vps34-deficient animals developed increased metastases in response to challenge with B16 melanoma ce

203 the treatment of non-small cell lung cancer metastases in the brain.

204 nd open liver resection for colorectal liver metastases in the elderly.

205 Imaging revealed numerous metastases in the lungs, liver, and brain.

206 formity of known driver gene mutations among metastases in the same patient has critical and encourag

207 rterial therapy options for colorectal liver metastases include chemoinfusion via a hepatic arterial

208 CNS metastases-including brain and leptomeningeal metastases

209 cancers that was associated with lymph-node metastases (INHBB, AXL, FGFR1, and PDFGRB) and upregulat

210 (HR, 0.59; 95% CI, 0.46-0.74; P < .001) and metastases involving the gastrointestinal tract (HR, 0.6

211 Reconstructing the evolutionary history of metastases is critical for understanding their basic bio

212 t evidence affecting the treatment of spinal metastases is integrated into a decision framework that

213 However, the presence of lung metastases is markedly suppressed in Muc4(ko)/NDL mice.

214 e conclude that the T-cell response to brain metastases is not a surrogate of local tumor invasion, p

215 e dissection for patients with sentinel-node metastases is not clear.

216 However, the genetics of metastases largely reflects that of the primary tumor in

217 as, it is associated with a risk of cerebral metastases lower than 2%.

218 reased (18)F-FET uptake, and only a third of metastases < 1.0 cm were (18)F-FET-negative, most likely

219 erapy itself induces chemoresistance of bone metastases, mediated by osteoblast Jagged1-induced tumor

220 ned specific eligibility criteria (ie, brain metastases, minimum age, HIV infection, and organ dysfun

221 dney and liver metastases in an experimental metastases mouse model.

222 ith multifocal, bilobar neuroendocrine liver metastases (NELM) after the first transarterial chemoemb

223 None of the patients experienced metastases nor died of iris melanoma.

224 r (WHO performance status 0 or 1) with liver metastases not suitable for curative resection or ablati

225 sitive non-small-cell lung cancer with brain metastases now have the potential to achieve a prolonged

226 Bone metastases occur in approximately 70% of metastatic brea

227 Distant metastases occur in half of patients and are responsible

228 t pCR had a relative risk for positive nodal metastases of 7.4 (95% CI, 3.7-14.8; P < .001) compared

229 In one patient with THSD7A-associated MN and metastases of an endometrial carcinoma, immunohistochemi

230 modality for response assessment of hepatic metastases of breast cancer according to the RECIST crit

231 nst glioblastoma but generally fail in brain metastases of breast cancer.

232 oglycan versican is implicated in growth and metastases of several cancers.

233 of 244 patients (34%) developed perihepatic metastases, of whom 55 (23%) developed LPI after median

234 primary tumor, and surgical resection of the metastases offers the only opportunity for long-term sur

235 iatric brain malignancy, with leptomeningeal metastases often present at diagnosis and recurrence ass

236 ssimistic analysis") or assumed negative for metastases ("optimistic analysis").

237 ients were excluded if they had active brain metastases or active autoimmune disease requiring system

238 Outcomes for OS presenting with unresectable metastases or recurrent disease, or in those older than

239 t can be considered for patients at risk for metastases or who exhibit symptoms or other evidence of

240 vocal scans were either assumed positive for metastases ("pessimistic analysis") or assumed negative

241 antibody to mice bearing experimental liver metastases phenocopied neutrophil depletion by reducing

242 Untreated metastases predominantly show increased (18)F-FET uptake

243 For overall survival and distant metastases, pretreatment compactness improved the c-inde

244 Blue node metastases rate was 4.5% (2/44).

245 y, 56 patients were enrolled, all with liver metastases refractory to systemic therapy and ineligible

246 ts, beta3 was significantly elevated on bone metastases relative to primary tumors from the same pati

247 Metastases remain the major cause of death from cancer.

248 s), but detection rates, especially of liver metastases, remain limited even with PET/CT.

249 the development and progression of pulmonary metastases remains a significant problem.

250 recapitulating the progression of multifoci metastases seen in patients.

251 /5 liver metastases, and the same four liver metastases shared mutations in 32 genes, including mutat

252 A single 8-Gy radiotherapy dose for bone metastases should be offered to all patients, even those

253 ents with treated or clinically stable brain metastases should be routinely included in trials and on

254 with breast cancer who have evidence of bone metastases should be treated with BMAs.

255 sion Women without sentinel lymph node (SLN) metastases should not receive axillary lymph node dissec

256 ays 10 and 42 after radiotherapy with a bone metastases-specific QOL tool.

257 n surrounding the tumor cells, rendering the metastases susceptible to mucosal immunity.

258 >2-fold) xenograft tumors in mice, with more metastases, than cells not expressing the fusion protein

259 formed smaller xenograft tumors, with fewer metastases, than control HUH7 cells.

260 models exist to readily investigate distant metastases that are mainly responsible for mortality in

261 localizing immunohistochemically ER-positive metastases that lack receptor-binding functionality.

262 he first description of a patient with brain metastases that were characterised by restricted diffusi

263 Skeletal metastases, the leading cause of death in advanced breas

264 es for the detection of probable spinal bone metastases, thereby providing an opportunity to reduce i

265 ancer and support comprehensive profiling of metastases to inform clinical care.

266 Bioluminescent imaging of tumor metastases to the liver, lungs, and spleen revealed that

267 peritoneal sarcoma in the pelvic region with metastases to the liver.

268 imaging (DWI) to assess the response of bone metastases to treatment in patients with metastatic cast

269 urvival of patients with sentinel lymph node metastases treated with breast-conserving therapy and se

270 tion was limited to patients with lymph node metastases, tumors 4 cm or larger, or local extension.

271 with four factors: presence of extrahepatic metastases, tumour involvement of the liver, planned use

272 verall, patients with gastrointestinal tract metastases undergoing complete, curative resection deriv

273 s 1 (TIMP1) in primary pancreatic tumors and metastases using both in vitro techniques and animal mod

274 survival among the entire cohort with brain metastases was 10.0 months.

275 The median follow-up after the diagnosis of metastases was 7.2 y (0.4-31 y).

276 on of AR and ER in biopsies of corresponding metastases was analyzed.

277 Notably, growth of primary tumors and metastases was both strongly inhibited in C3-deficient m

278 immune checkpoint blockade immunotherapy for metastases was compromised when NK cells lacked heparana

279 onsiderations for patients with active brain metastases was developed.

280 netic similarity among the founding cells of metastases was higher than that expected for any two cel

281 ssage cultures from primary tumors and liver metastases we show that ATM loss accelerates Kras-induce

282 xon 19 mutation, and absence of extracranial metastases were associated with improved OS.

283 Patients with metastases were excluded.

284 Lesions atypical for PC metastases were found in 49 (6.4%) of 764 patients, and

285 Nodal metastases were identified in the sentinel lymph nodes o

286 11.8) performed for suspected vertebral bone metastases were included in this retrospective, institut

287 The bony metastases were not evident on the CT scan and the soft

288 e treated with adjuvant chemotherapy, and no metastases were recorded in a median follow-up time of 7

289 rognostic importance of LPI and hematogenous metastases were studied by using univariate and multivar

290 e inhibitor and patients with leptomeningeal metastases who had been pretreated with an EGFR tyrosine

291 afety profile in patients with NSCLC and CNS metastases who had either never received a tyrosine kina

292 patients with either brain or leptomeningeal metastases who had never received an EGFR tyrosine kinas

293 stases had a diameter of </= 1.0 cm, whereas metastases with a > 1.0 cm diameter all showed pathologi

294 LC tumor xenografts as well as distant organ metastases with high sensitivity.

295 al benefit in patients with colorectal liver metastases with liver-dominant disease after chemotherap

296 triggers the evolution of therapy-resistant metastases, with potentially broad implications for thei

297 weighted sequences for the detection of bone metastases, with the hypothesis that diagnostic performa

298 ative genomic analyses of primary tumors and metastases within individuals with pancreatic cancer hav

299 Patients with newly diagnosed brain metastases without prior local therapy and (18)F-FET PET

300 otherapy type (vinflunine vs taxanes), liver metastases (yes vs no), and number of prognostic factors